The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
08-Aug-16
$87 million
Target:
Aquasana, Inc.
Acquiror:
A. O. Smith Corporation
Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton
28-Jul-16
$80 million
Target:
BioD, LLC
Acquiror:
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
28-Jun-16
$NA
Target:
US rights to an authorized generic version of Adderall XR
Acquiror:
Prasco Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to an authorized generic version of Adderall XR
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
21-Jun-16
$586 million
Target:
US rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Impax Laboratories, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
16-Jun-16
$40 million
Target:
US rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Sagent Pharmaceuticals, Inc.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 5 generic injectable drug products to Sagent Pharmaceuticals, Inc.
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
04-May-16
$NA
Target:
Affinia Group
Acquiror:
MANN+HUMMEL GmbH
Advised MANN+HUMMEL GmbH, a leading global manufacturer of filtration solutions, on the acquisition of the global filtration operations (excluding the Affinia South America operations) of Affinia Group
04-May-16
$NA
Target:
Portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
Acquiror:
Ligand Pharmaceuticals
Advised CorMatrix Cardiovascular, a leading medical device company with a differentiated extracellular matrix technology, on the sale of a portfolio of synthetic royalty and milestone rights on multiple cardiovascular programs
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
19-Apr-16
$NA
Target:
Total Care Medicaid Plan
Acquiror:
Molina Healthcare, Inc.
Advised Molina Healthcare Inc., a provider of managed health care services under the Medicaid and Medicare programs, on the acquisition of Universal American’s Total Care Medicaid plan
18-Mar-16
$NA
Target:
Sewells Group
Acquiror:
MSX International
Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East
16-Mar-16
$942 million
Target:
Rofin-Sinar Technologies, Inc.
Acquiror:
Coherent, Inc.
Advised Rofin-Sinar Technologies, Inc., a leading manufacturer of industrial laser sources and laser-based solutions and components, on its sale to Coherent, Inc., a leading provider of lasers and laser-based technology for scientific, commercial and industrial customers
07-Mar-16
$NA
Target:
Boehringer Ingelheim
Acquiror:
AbbVie
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
10-Dec-15
$855 million
Target:
Blount International, Inc.
Acquiror:
American Securities LLC and P2 Capital Partners, LLC
Advised the Special Committee of the Board of Directors of Blount International Inc., a leading global manufacturer of saw chains, guide bars, sprockets and other equipment for the forestry, agriculture and construction markets, on its sale to American Securities LLC and P2 Capital Partners, LLC
07-Dec-15
$755 million
Target:
Stork
Acquiror:
Fluor Corporation
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
12-Nov-15
$406 million
Target:
Lane Industries Incorporated
Acquiror:
Salini Impregilo S.p.A.
Advised Lane Industries Incorporated, a privately-held construction company specializing in heavy civil projects, including design-build and public private partnerships, on its sale to Salini Impregilo S.p.A.
29-Oct-15
$275 million
Target:
Aesynt, Inc.
Acquiror:
Omnicell, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
14-Oct-15
$330 million
Target:
Professional Service Industries, Inc.
Acquiror:
Intertek Group plc
Advised Intertek Group plc, a leading quality solutions provider to industries worldwide, on its $330 million acquisition of Professional Service Industries, Inc. (“PSI”), a leading US based provider of testing and assurance services to commercial and civil construction markets